Related to ViroPharma Pays Meritage Initial $7.5M for Option to Acquire Firm for EoE Drug

• FDA OKs Novartis' Drug for Childhood Arthritis
  
• Instem Expands Into Early Trials with Logos Purchase
  
• AbbVie, Alvine Make $70M Celiac Disease Drug Deal
  
• Quest Acquires Concentra’s Toxicology, Clinical Lab Business
  
• Oxford BioMedica to Obtain $250K to Support Gene Therapy for Stargardt Disease
  
• FDA Stalls Approval of Genzyme’s Pompe Disease Drug
  
• FDA Sanctions Alexion’s RI Production Plant for Commercial Supply of Soliris
  
• Shire Gains EC Nod for Gaucher Disease Treatment
  
• Shire Pays Acceleron $45M Up Front for Neuromuscular Disease Candidates
  
• GSK Pays Amicus $30M Up Front for Phase III Fabry Disease Drug
  
• EMA Road Map Aims to Stimulate Drug Development for Unmet Medical Needs and Rare and Neglected Diseases
  
• Synageva Raises $25M Through Private Placement with Existing Investors
  
• Pfizer to Attack Lysosomal Storage Diseases with Zacharon’s Small Molecule Approach
  
• Pfizer’s TTR-FAP Candidate Slows Disease Progression in Pivotal Trial Extension
  
• FDA Clears Expanded Access Program for Edison’s Mitochondrial Diseases Candidate
  
• Synageva Merges with Trimeris in All-Stock Deal
  
• Pfizer’s Vyndaqel Gets EC Approval for Transthyretin Familial Amyloid Polyneuropathy Therapy
  
• Alexion Pays $610M to Buy Enobia for Hypophosphatasia ERT Candidate
  
• Synageva, Mitsubishi Tanabe Pharma Add Second Rare Disease Program to Alliance
  
• Protalix, Pfizer Report FDA Approval of Plant-Derived Gaucher Disease ERT Elelyso